Skip to main content
Log in

Allogeneic bone marrow transplantation for refractory mantle cell lymphoma

  • CASE REPORT
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

 We report about a 28-year-old woman with relapsed mantle cell lymphoma (MCL, centrocytic lymphoma according to the Kiel classification) refractory to salvage chemotherapy. The patient underwent allogeneic bone marrow transplantation from a HLA-identical brother after myeloablative chemotherapy consisting of busulfan, etoposide, and cyclophosphamide. The patient experienced hepatic toxicity (grade I), mucositis (grade II) according the Bearman scale, and graft versus host disease of the skin (grade II) and showed stable engraftment with complete chimerism on day 15 after bone marrow transplantation. Eight years after transplantation, the patient is still disease free and in good condition without any late side effects. This report suggests a curative potential of allogeneic stem cell transplantation in MCL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 23 December 1999 / Accepted: 28 March 2000

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kröger, N., Hoffknecht, M., Krüger, W. et al. Allogeneic bone marrow transplantation for refractory mantle cell lymphoma. Ann Hematol 79, 578–580 (2000). https://doi.org/10.1007/s002770000196

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002770000196

Navigation